Back to Search
Start Over
Prevalence of rapidly progressive osteoarthritis of the hip following intra-articular steroid injections.
- Source :
- PM & R: Journal of Injury, Function & Rehabilitation; Mar2023, Vol. 15 Issue 3, p259-264, 6p
- Publication Year :
- 2023
-
Abstract
- <bold>Introduction: </bold>Numerous studies have indicated that intra-articular steroid injections to the hip are beneficial for short-term pain relief. However, recent studies have drawn concerns of rapidly progressive osteoarthritis of the hip (RPOH) following intra-articular steroid injections. The prevalence of RPOH following intra-articular steroid injections varies widely in the literature.<bold>Objective: </bold>To identify the prevalence of RPOH following intra-articular steroid injections, and to compare baseline characteristics between patients with and without RPOH.<bold>Design: </bold>Case series.<bold>Setting: </bold>Tertiary academic hospital.<bold>Patients: </bold>A total of 924 patients (median [interquartile range; IQR] age: 59 [45-70] years; 579 female) who received an intra-articular hip steroid/anesthetic injection from January 2016 to March 2018 and had available pre- and post-injection imaging (prior to surgical intervention) were included in the study.<bold>Interventions: </bold>Baseline and injection-related data-including demographics, age, body mass index, medical history, laterality, and steroid type-were collected from electronic medical records.<bold>Main Outcome Measures: </bold>Post-injection RPOH was determined via imaging review by a physiatry fellow, followed by an attending physiatrist and a musculoskeletal radiologist to confirm findings.<bold>Results: </bold>The majority of patients received unilateral injections into the hip, and the most common steroids used were triamcinolone and methylprednisolone. Review of pre- and post-injection imaging revealed 26 cases of RPOH, for an overall prevalence of 2.8% (95% confidence interval [CI] 1.9%-4.1%). Compared to those without RPOH, patients with RPOH were significantly older (median age [IQR]: 64 [60-73] vs. 59 [44-70] years, p = .003) and had a shorter duration of symptoms prior to their injections (median [IQR]: 3 vs. 12 [6-36] months, pā<ā.001). Adjusted regression analyses showed that age was associated with greater odds of RPOH (odds ratio [OR], 95% CI: 1.04, 1.01 to 1.07; p = .003).<bold>Conclusions: </bold>The prevalence of RPOH following intra-articular steroid injections into the hip was lower than previously reported but still clinically relevant. This should be considered when counseling patients prior to intra-articular hip steroid injections. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 19341482
- Volume :
- 15
- Issue :
- 3
- Database :
- Supplemental Index
- Journal :
- PM & R: Journal of Injury, Function & Rehabilitation
- Publication Type :
- Academic Journal
- Accession number :
- 162595537
- Full Text :
- https://doi.org/10.1002/pmrj.12853